Termgrid supports Leveraged Finance Fights Melanoma 

Termgrid is delighted to support Leveraged Finance Fights Melanoma (LFFM) sponsoring its inaugural London event. Termgrid CEO, Dipish Rai, will join the London Host Committee as LFFM brings together the leveraged finance community.

Each year, the most influential leaders in leveraged finance and private equity come together for a cause that transcends business: fighting melanoma. Through the annual LFFM event in New York, this community has raised over £21 million, fueling critical research and breakthroughs led by the Melanoma Research Alliance (MRA) – the largest and highest-rated non-profit funder of melanoma research in the world.

Thanks to the support of the LFFM community, the melanoma field has seen unparalleled progress. Since the inaugural LFFM, 17 new FDA-approved therapies for melanoma have revolutionized cancer treatment, making the field a beacon of scientific excellence and innovation. These advancements have rippled across oncology, extending hope and improved outcomes to patients battling over 30 other types of cancer. Today, thanks to this progress, countless patients are living longer, fuller lives.

This extraordinary achievement is a testament to the commitment of the community who understand the power of purpose-driven collaboration. The New York event has become more than a fundraiser – it’s a sold-out, influential gathering where over 110 firms unite annually, blending philanthropy with powerful networking opportunities that drive both impact and connection.

“We are honored to join the London host community for this exciting event. We have seen the extraordinary work being done by leveraged finance professionals through the LFFM initiative. Research advancements, supported by the LFFM, have transformed the melanoma landscape and we hope that we can continue the momentum with this important work,” said Dipish Rai, CEO, Termgrid.